Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Musculoskeletal | Family Medicine
Disease Category: Multiple Sclerosis
Location: United States, IL
A 6 month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5mg/day in patients with relapsing remitting MS who are candidates for MS therapy change from previous disease modifying therapy (EPOC).
The purpose of this study is to evaluate patient-reported outcomes and physician assessment of a change in therapy for patients with remitting-relapsing multiple sclerosis when changing a patient's current multiple sclerosis therapy to fingolimod or maintaining the current therapy.
Please contact Alexian Brothers for more information on participation.
Alexian Brothers Hospital Network
800 Biesterfield Road
Brock Building First Floor
Elk Grove Village, IL 60007
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these